Microba Life Sciences Limited (FRA:F3Y)

Market Cap	24.26M -26.2%
Revenue (ttm)	8.47M -11.8%
Net Income	-11.22M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0290
Previous Close	0.0290
Day's Range	0.0290 - 0.0290
52-Week Range	0.0175 - 0.0525
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 15, 2026

About Microba Life Sciences

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution...

• Industry: Medical Laboratories
• Founded: 2017
• Country: Australia
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: F3Y

Financial Performance

In fiscal year 2025, Microba Life Sciences's revenue was 15.67 million, an increase of 29.60% compared to the previous year's 12.09 million. Losses were -14.94 million, -25.07% less than in 2024.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error